Fortress Biotech, Inc. (FBIOP) Current Deferred Revenue (2016 - 2023)
Fortress Biotech (FBIOP) posted quarterly Current Deferred Revenue of $547000.0 for Q1 2023, down 73.11% year-over-year from $2.0 million in Q1 2022, and down 24.86% quarter-over-quarter from $728000.0 in Q4 2022.
Fortress Biotech, Inc. (FBIOP) Current Deferred Revenue (2016 - 2023) Analysis & Trends
Fortress Biotech's Current Deferred Revenue history runs 6 years deep, the most recent figure standing at $547000.0 for Q1 2023.
- In Q1 2023, Current Deferred Revenue fell 73.11% year-over-year to $547000.0; the TTM figure through Mar 2023 stood at $547000.0 (down 73.11% YoY), while the FY2022 annual figure was $728000.0, down 72.12% from the prior year.
- Current Deferred Revenue for Q1 2023 stood at $547000.0, down from $728000.0 in the prior quarter.
- The five-year high for Current Deferred Revenue was $7.2 million in Q1 2021, with the low at $547000.0 in Q1 2023.
- The 3-year median for Current Deferred Revenue is $2.0 million (2022), against an average of $2.6 million.
- The sharpest annual moves came in 2022 and 2023: Current Deferred Revenue plunged 67.41% in 2022, then slumped 73.11% in 2023.
- Fortress Biotech's Current Deferred Revenue stood at $2.6 million in 2021, then plunged by 72.12% to $728000.0 in 2022, then fell by 24.86% to $547000.0 in 2023.
- Business Quant data shows FBIOP's Current Deferred Revenue at $547000.0 in Q1 2023, $728000.0 in Q4 2022, and $1.1 million in Q3 2022.
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 547,000.00 |
| Dec 31, 2022 | 728,000.00 |
| Sep 30, 2022 | 1.09 Mn |
| Jun 30, 2022 | 1.46 Mn |
| Mar 31, 2022 | 2.03 Mn |
| Dec 31, 2021 | 2.61 Mn |
| Sep 30, 2021 | 3.35 Mn |
| Jun 30, 2021 | 4.80 Mn |
| Mar 31, 2021 | 7.20 Mn |
| Sep 30, 2018 | 155,000.00 |
| Jun 30, 2018 | 681,000.00 |
| Mar 31, 2018 | 690,000.00 |
| Sep 30, 2017 | 500,000.00 |
| Jun 30, 2017 | 891,000.00 |
| Mar 31, 2017 | 943,000.00 |
| Dec 31, 2016 | 995,000.00 |
| Sep 30, 2016 | 300,000.00 |